Revitalizing Pharmaceutical R&D: The value of real world evidence
Published: March 2, 2015 with Volker Rönicke and Thomas Solbach

Pharmaceutical companies face a major challenge that threatens reimbursement and value capture: The potential disruption from real world evidence (RWE) as a factor in evaluating new drugs. The emergence of health technology assessment practices today makes it still more difficult to achieve attractive reimbursement value for newly launched products.

 

© 2016 PwC. All rights reserved.
PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.